Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 31;188(12):2188-2195.
doi: 10.1093/aje/kwz088.

Cancer Survivorship and Subclinical Myocardial Damage

Affiliations

Cancer Survivorship and Subclinical Myocardial Damage

Roberta Florido et al. Am J Epidemiol. .

Abstract

Cancer survivors might have an excess risk of cardiovascular disease (CVD) resulting from toxicities of cancer therapies and a high burden of CVD risk factors. We sought to evaluate the association of cancer survivorship with subclinical myocardial damage, as assessed by elevated high-sensitivity cardiac troponin T (hs-cTnT) test results. We included 3,512 participants of the Atherosclerosis Risk in Communities Study who attended visit 5 (2011-2013) and were free of CVD (coronary heart disease, heart failure, or stroke). We used multivariate logistic regression to evaluate the cross-sectional associations of survivorship from any, non-sex-related, and sex-related cancers (e.g., breast, prostate) with elevated hs-cTnT (≥14 ng/L). Of 3,512 participants (mean age, 76 years; 62% women; 21% black), 19% were cancer survivors. Cancer survivors had significantly higher odds of elevated hs-cTnT (OR = 1.26, 95% CI: 1.03, 1.53). Results were similar for survivors of non-sex-related and colorectal cancers, but there was no association between survivorship from breast and prostate cancers and elevated hs-cTnT. Results were similar after additional adjustments for CVD risk factors. Survivors of some cancers might be more likely to have elevated hs-cTnT than persons without prior cancer. The excess burden of subclinical myocardial damage in this population might not be fully explained by traditional CVD risk factors.

Keywords: ARIC; biomarkers; cancer; cardiovascular disease; hs-cTnT.

PubMed Disclaimer

References

    1. Miller KD, Siegel RL, Lin CC, et al. . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–289. - PubMed
    1. Oeffinger KC, Mertens AC, Sklar CA, et al. . Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–1582. - PubMed
    1. Armstrong GT, Oeffinger KC, Chen Y, et al. . Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673–3680. - PMC - PubMed
    1. Armenian SH, Lacchetti C, Barac A, et al. . Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893–911. - PubMed
    1. de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA. 2013;309(21):2262–2269. - PubMed

Publication types